~~<i id='82CF427579'><strike id='82CF427579'><tt id='82CF427579'><pre id='82CF427579'></pre></tt></strike></i>~~

Home» knowledge» explore

explore

author：explore 2025-08-07 04:35:53 Page View：16239

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare bonuses could stop drug shortages under Senate plan
Next article： Alkermes shareholders re

explore

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Printout prescription drug information shouldn’t go digital

AdobeGettinganewprescriptioncanbeoverwhelming:medicationschedules,foodstoeatoravoid,interactionsbetw

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Medicare drug price lawsuits could be good politics for Biden

AdobeWASHINGTON—PharmaceuticalcompaniesaredoinganythingtheycantostopPresidentBiden’sMedicareprogramf